Traveler-based Genomic Surveillance Program
Closed Solicitation Posted
- Solicitation number
- RFP75D30124R72969
- Agency
-
CDC Office of Acquisition Services
Centers for Disease Control and Prevention, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 541380 Testing Laboratories and Services
- Place of performance
- United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of Health and Human Services Centers for Disease Control and Prevention (CDC) Office of Acquisition Services is seeking proposals for the Traveler-based Genomic Surveillance (TGS) program. The purpose of TGS is to utilize samples from international travelers (clinical and environmental) to test, sequence, and monitor trends of SARS-CoV-2 and other pathogens in order to provide early detection of new variants and fill gaps in global biosurveillance. Key contract requirements include establishing sample collection sites at 6 major U.S. international airports, conducting RT-PCR testing and genetic sequencing on all positive samples with a 10-day turnaround, and providing weekly data reporting to the CDC. Proposals are due by August 9, 2024.
This solicitation was originally set aside for small businesses under NAICS code 541380 - Testing Laboratories and Services, but the set-aside requirement was removed due to lack of capable small business responses during market research. The contract has a base period of performance from August 26, 2024 to August 25, 2027, with firm-fixed-price contract line items and optional surge testing and pilot task orders. The place of performance is the United States.
Notice text
4 versions
Update #4 · Latest ·
Revised Solicitation and Questions and Responses Updated posted 7/31/2024. For the solicitation CLIN 2004 period of performance was updated to 8/26/2025 - 8/25/2026. Section F was also updated.
Questions and Responses posted 7/18/2024.
Solicitation Revision #1 7/10/2024 - Section A (1)(d) language that inidcated a small business set-aside is removed. See updated solicitation document.
The Traveler-based Genomic Surveillance program (TGS) plays an important role in U.S. national biosecurity through its two major goals: (1) early detection of new SARS-CoV-2 variants and other pathogens and (2) filling in gaps in global biosurveillance.
The purpose of TGS is to utilize samples from travelers (clinical and environmental) to test, sequence and monitor trends of SARS-CoV-2 and other important pathogens and public health threats ( e.g. antimicrobial resistance) . TGS is voluntary and enrolls travelers from a wide array of countries. Prioritization of arriving flights is based on factors such as travel volume, geographic region, available sequencing data, disease prevalence and seasonality, etc. TGS is flexible and nimble and maintains the ability to surge capacity depending on public health needs. The de-identified raw data and samples collected belong to CDC. Samples from travelers undergo reverse transcription PCR (RT-PCR) testing and genetic sequencing on all positive samples. The turn-around-time from sample collection to reporting of sequencing results is within 10 days. The program leverages a variety of sampling modalities, including individual testing, pooled testing, wastewater testing, and air sampling. TGS uses a variety of molecular testing techniques and sequencing approaches.
The Traveler-based Genomic Surveillance program (TGS) plays an important role in U.S. national biosecurity through its two major goals: (1) early detection of new SARS-CoV-2 variants and other pathogens and (2) filling in gaps in global biosurveillance.
The purpose of TGS is to utilize samples from travelers (clinical and environmental) to test, sequence and monitor trends of SARS-CoV-2 and other important pathogens and public health threats ( e.g. antimicrobial resistance) . TGS is voluntary and enrolls travelers from a wide array of countries. Prioritization of arriving flights is based on factors such as travel volume, geographic region, available sequencing data, disease prevalence and seasonality, etc. TGS is flexible and nimble and maintains the ability to surge capacity depending on public health needs. The de-identified raw data and samples collected belong to CDC. Samples from travelers undergo reverse transcription PCR (RT-PCR) testing and genetic sequencing on all positive samples. The turn-around-time from sample collection to reporting of sequencing results is within 10 days. The program leverages a variety of sampling modalities, including individual testing, pooled testing, wastewater testing, and air sampling. TGS uses a variety of molecular testing techniques and sequencing approaches.
Update #3 ·
Questions and Responses posted 7/18/2024.
Solicitation Revision #1 7/10/2024 - Section A (1)(d) language that inidcated a small business set-aside is removed. See updated solicitation document.
The Traveler-based Genomic Surveillance program (TGS) plays an important role in U.S. national biosecurity through its two major goals: (1) early detection of new SARS-CoV-2 variants and other pathogens and (2) filling in gaps in global biosurveillance.
The purpose of TGS is to utilize samples from travelers (clinical and environmental) to test, sequence and monitor trends of SARS-CoV-2 and other important pathogens and public health threats ( e.g. antimicrobial resistance) . TGS is voluntary and enrolls travelers from a wide array of countries. Prioritization of arriving flights is based on factors such as travel volume, geographic region, available sequencing data, disease prevalence and seasonality, etc. TGS is flexible and nimble and maintains the ability to surge capacity depending on public health needs. The de-identified raw data and samples collected belong to CDC. Samples from travelers undergo reverse transcription PCR (RT-PCR) testing and genetic sequencing on all positive samples. The turn-around-time from sample collection to reporting of sequencing results is within 10 days. The program leverages a variety of sampling modalities, including individual testing, pooled testing, wastewater testing, and air sampling. TGS uses a variety of molecular testing techniques and sequencing approaches.
The Traveler-based Genomic Surveillance program (TGS) plays an important role in U.S. national biosecurity through its two major goals: (1) early detection of new SARS-CoV-2 variants and other pathogens and (2) filling in gaps in global biosurveillance.
The purpose of TGS is to utilize samples from travelers (clinical and environmental) to test, sequence and monitor trends of SARS-CoV-2 and other important pathogens and public health threats ( e.g. antimicrobial resistance) . TGS is voluntary and enrolls travelers from a wide array of countries. Prioritization of arriving flights is based on factors such as travel volume, geographic region, available sequencing data, disease prevalence and seasonality, etc. TGS is flexible and nimble and maintains the ability to surge capacity depending on public health needs. The de-identified raw data and samples collected belong to CDC. Samples from travelers undergo reverse transcription PCR (RT-PCR) testing and genetic sequencing on all positive samples. The turn-around-time from sample collection to reporting of sequencing results is within 10 days. The program leverages a variety of sampling modalities, including individual testing, pooled testing, wastewater testing, and air sampling. TGS uses a variety of molecular testing techniques and sequencing approaches.
Update #2 ·
Solicitation Revision #1 7/10/2024 - Section A (1)(d) language that inidcated a small business set-aside is removed. See updated solicitation document.
The Traveler-based Genomic Surveillance program (TGS) plays an important role in U.S. national biosecurity through its two major goals: (1) early detection of new SARS-CoV-2 variants and other pathogens and (2) filling in gaps in global biosurveillance.
The purpose of TGS is to utilize samples from travelers (clinical and environmental) to test, sequence and monitor trends of SARS-CoV-2 and other important pathogens and public health threats ( e.g. antimicrobial resistance) . TGS is voluntary and enrolls travelers from a wide array of countries. Prioritization of arriving flights is based on factors such as travel volume, geographic region, available sequencing data, disease prevalence and seasonality, etc. TGS is flexible and nimble and maintains the ability to surge capacity depending on public health needs. The de-identified raw data and samples collected belong to CDC. Samples from travelers undergo reverse transcription PCR (RT-PCR) testing and genetic sequencing on all positive samples. The turn-around-time from sample collection to reporting of sequencing results is within 10 days. The program leverages a variety of sampling modalities, including individual testing, pooled testing, wastewater testing, and air sampling. TGS uses a variety of molecular testing techniques and sequencing approaches.
The Traveler-based Genomic Surveillance program (TGS) plays an important role in U.S. national biosecurity through its two major goals: (1) early detection of new SARS-CoV-2 variants and other pathogens and (2) filling in gaps in global biosurveillance.
The purpose of TGS is to utilize samples from travelers (clinical and environmental) to test, sequence and monitor trends of SARS-CoV-2 and other important pathogens and public health threats ( e.g. antimicrobial resistance) . TGS is voluntary and enrolls travelers from a wide array of countries. Prioritization of arriving flights is based on factors such as travel volume, geographic region, available sequencing data, disease prevalence and seasonality, etc. TGS is flexible and nimble and maintains the ability to surge capacity depending on public health needs. The de-identified raw data and samples collected belong to CDC. Samples from travelers undergo reverse transcription PCR (RT-PCR) testing and genetic sequencing on all positive samples. The turn-around-time from sample collection to reporting of sequencing results is within 10 days. The program leverages a variety of sampling modalities, including individual testing, pooled testing, wastewater testing, and air sampling. TGS uses a variety of molecular testing techniques and sequencing approaches.
Update #1 ·
The Traveler-based Genomic Surveillance program (TGS) plays an important role in U.S. national biosecurity through its two major goals: (1) early detection of new SARS-CoV-2 variants and other pathogens and (2) filling in gaps in global biosurveillance.
The purpose of TGS is to utilize samples from travelers (clinical and environmental) to test, sequence and monitor trends of SARS-CoV-2 and other important pathogens and public health threats ( e.g. antimicrobial resistance) . TGS is voluntary and enrolls travelers from a wide array of countries. Prioritization of arriving flights is based on factors such as travel volume, geographic region, available sequencing data, disease prevalence and seasonality, etc. TGS is flexible and nimble and maintains the ability to surge capacity depending on public health needs. The de-identified raw data and samples collected belong to CDC. Samples from travelers undergo reverse transcription PCR (RT-PCR) testing and genetic sequencing on all positive samples. The turn-around-time from sample collection to reporting of sequencing results is within 10 days. The program leverages a variety of sampling modalities, including individual testing, pooled testing, wastewater testing, and air sampling. TGS uses a variety of molecular testing techniques and sequencing approaches.
The Traveler-based Genomic Surveillance program (TGS) plays an important role in U.S. national biosecurity through its two major goals: (1) early detection of new SARS-CoV-2 variants and other pathogens and (2) filling in gaps in global biosurveillance.
The purpose of TGS is to utilize samples from travelers (clinical and environmental) to test, sequence and monitor trends of SARS-CoV-2 and other important pathogens and public health threats ( e.g. antimicrobial resistance) . TGS is voluntary and enrolls travelers from a wide array of countries. Prioritization of arriving flights is based on factors such as travel volume, geographic region, available sequencing data, disease prevalence and seasonality, etc. TGS is flexible and nimble and maintains the ability to surge capacity depending on public health needs. The de-identified raw data and samples collected belong to CDC. Samples from travelers undergo reverse transcription PCR (RT-PCR) testing and genetic sequencing on all positive samples. The turn-around-time from sample collection to reporting of sequencing results is within 10 days. The program leverages a variety of sampling modalities, including individual testing, pooled testing, wastewater testing, and air sampling. TGS uses a variety of molecular testing techniques and sequencing approaches.
Files
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| Amplicon sequencing services | Office of Acquisitions and Grants | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity